Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 18, Issue 25, Pages 3804-3811Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161212802002805
Keywords
Immunotherapy; vaccine; epithelial ovarian cancer; tumor antigen; p53; lymphocyte; immunization; clinical trial
Categories
Ask authors/readers for more resources
This review discusses the results of different immunization strategies, identifies possible drawbacks in study design and provides potential solutions for augmentation of clinical efficacy. A potential target for cancer immunotherapy is p53, as approximately 50% of ovarian cancer cells carry p53 mutations. Therefore we review the immunological and clinical responses observed in ovarian cancer patients vaccinated with p53 targeting vaccines in particular. In most studies antigen-specific vaccine-induced immunological responses were observed. Unfortunately, no clinical responses with significant reduction of tumor-burden have been reported. Based on the currently available results we emphasize the necessity of multimodality treatment of ovarian cancer, combining classical cytoreductive surgery, (neo) adjuvant chemotherapy, immunotherapy and/or targeted therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available